Intravenous Neonatal Central Access Safety Trial

NARecruitingINTERVENTIONAL
Enrollment

736

Participants

Timeline

Start Date

January 1, 2023

Primary Completion Date

June 30, 2026

Study Completion Date

June 30, 2026

Conditions
Newborn ComplicationCatheter Complications
Interventions
DEVICE

In-line filter

"All infusions, with the exception of some solutions (eg blood products), will be subjected to filtration. The aqueous solutions (parenteral therapy and drugs) will be administered through 0.2 μm filters which will be replaced every 96 h; the lipid emulsions will be administered through 1.2 μm filters which will be replaced every 24 h.~In case of emergency, life-saving drugs will be administered with bolus modality though the infusion line closer to the patient without the need for filtration.~In case of drugs/solutions not supported by filtration (eg blood products), they will be administered through a dedicated unfiltered access, which will be removed as soon as the drug is no longer needed."

Trial Locations (1)

10100

RECRUITING

Città della Salute e della Scienza, Torino

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Pall Corporation

OTHER

lead

University of Turin, Italy

OTHER

NCT05537389 - Intravenous Neonatal Central Access Safety Trial | Biotech Hunter | Biotech Hunter